current user: public
If you have questions about the server, please let us know.

Query: [PET] KOG1054 Glutamate-gated AMPA-type ion channel receptor subunit GluR2 and related subunits, from VFDB

Results of FFAS03 search in PfamA32U
Master-slave alignment(slide right to see more) does not show gaps in the query sequence, use ali links to display alignment between query and templates.
    .   10    .   20    .   30    .   40    .   50    .   60    .   70    .   80    .   90    .  100    .  110    .  120    .  130    .  140    .  150    .  160    .  170    .  180    .  190    .  200    .  210    .  220    .  230    .  240    .  250    .  260    .  270    .  280    .  290    .  300    .  310    .  320    .  330    .  340    .  350    .  360    .  370    .  380    .  390    .  400    .  410    .  420    .  430    .  440    .  450    .  460    .  470    .  480    .  490    .  500    .  510    .  520    .  530    .  540    .  550    .  560    .  570    .  580    .  590    .  600    .  610    .  620    .  630    .  640    .  650    .  660    .  670    .  680    .  690    .  700    .  710    .  720    .  730    .  740    .  750    .  760    .  770    .  780    .  790    .  800    .  810    .  820    .  830    .  840    .  850    .  860    .  870    .  880    .  890    .  900    .
# Score Template Links and tools%idFirst MQHIFAFFCTGFLGAVVGANFPNNIQIGGLFPNQQSQEHAAFRFALSQLTEPPKLLPQIDIVNISDSFEMTYRFCSQFSKGVYAIFGFYERRTVNMLTSFCGALHVCFITPSFPVDTSNQFVLQLRPELQDALISIIDHYKWQKFVYIYDADRGLSVLQKVLDTAAEKNWQVTAVNILTTTEEGYRMLFQDLEKKKERLVVVDCESERLNAILGQIIKLEKNGIGYHYILANLGFMDIDLNKFKESGANVTGFQLVNYTDTIPAKIMQQWKNSDARDHTRVDWKRPKYTSALTYDGVKVMAEAFQSLRRQRIDISRRGNAGDCLANPAVPWGQGIDIQRALQQVRFEGLTGNVQFNEKGRRTNYTLHVIEMKHDSIRKIGYWNEDDKFVPAATDAQAGGDNSSVQNRTYIVTTILEDPYVMLKKNANQFEGNDRYEGYCVELAAEIAKHVGYSYRLEIVSDGKYGARDPDTKAWNGMVGELVYGRADVAVAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHSEEFEEGRDQTTSDQSNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLAKQTEIAYGTLEAGSTKEFFRRSKIAVFEKMWTYMKSAEPSVFVRTTEEGMIRVRKSKGKYAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSALRNPVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKDKTSALSLSNVAGVFYILIGGLGLAMLVALIEFCYKSRSESKRMKGFCLIPQQSINEAIRTSTLPRNSGAGASSGGSGENGRVVSHDFPKSMQSIPCMSHSSGMPLGATGLLast
1 -81.400PF00060.26; B7ZPS4_XENLA/162-426; Ligand-gated ion channel  ali follow..  34  1.......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................SKETWIGILVAYMVTSLCLFLVGRLSPCEWTELSTE----------QNNFTFLNSLWFGAGAFTLQGAEPHPKSVSARIIAVIWWIFSIVLVAAYIASFAAFLNSDSVQTTIQTFEDLVNQRTLEFGTINSSSTFQFFKNSKNPTYRMIYEYMDKRKDELLVKSFAEGVRRVRE--SNYAFLGESVMQDIMVAK-HCELARAPQIIAGRGYGIAASIDSQLIKQLSIAILEQTESGNIEYLRKKWWDNTCSM-----KRSAGWNPVQPHTLGGIFLILGIGL......................................................................................... 265
2 -53.100PF10613.9; H3CIB5_TETNG/416-530; Ligated ion channel L-glutamate- and glycine-binding site  ali follow..  56  1......................................................................................................................................................................................................................................................................................................................................................................................................................KTLIVTTILENPYVMRKDNYQDFQGNDQYEGFCVDMLREVADILKFSFKIKLVDDGLYGAPEP-NGSWTGMVGELINRKADLAVAAFTITSEREKVIDFSKPFMTLGISILYRVQ................................................................................................................................................................................................................................................................................................................................................................................................. 114
3 -42.800PF01094.28; GLR24_ARATH/47-394; Receptor family ligand binding region  ali follow..  15  1....................................LSLLAINMSLSDFYSSTRLLLNFADSRDDVVGAAAAALDLIKNKEVKAILGPRTTMQASFVIEVGQKSQVPIISFSATSPFLDPYFFRSTYDQVQAISEIIKVFGWREVVPVYENNAGEGIMPGLTDALQAINIRIPYRTVISATDDEISVDLLKLMTKPTRVFVVHMNRFLASRVFSKARETGLMKQGYAWILTNGVIDHLVLMNDIEAMQGVIGIRTHFPISEELQTFRSRLAKAFPVSEL-------NIYGLRAYDATTALAMAVEEAGTTNLTFSKMDGRNISDLEALSVSEYGPKLIRSLSQIQFKGLSGDYHFVDGQLHAS-VFEIVNVIDGG................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 348
4 -25.000PF00497.20; A6X2Q5_OCHA4/44-271; Bacterial extracellular solute-binding proteins, family 3  ali follow..  16  13...........................................................................................................................................................................................................................................................................................................................................................................................................................................VYMKDGKPAGFDVELMEGVAKQLGLAAEFK-------------DTRFTSLITGARANHFDVIASALYVTPERQKILNFI-PYIKAGSSLLVLKDAKFR-------------------------------------------------------------------------------------------------------------------------PANEKELCGK---IIGSMQGASWLPKLKALSEDYCAKNNLGAIETREFDTDAQVTQAL----RSGSVDVEFMDNVVAAELLKKFPDDYAVTSSLIYPIMVGVATTPQNKLFNAMNDAFAQMRKDGSYDALVKTYGME........................................................................................................................... 228
5 -14.500PF13458.6; Q2J527_FRACC/75-422; Periplasmic binding protein  ali follow..  9  1.......................EIKAGVLFPDTGPFARAGIDARFGEANAAGGV--KIVYSWRDDVSDPQLNLAAVQKEEVFGIIEGLGAVSG--SAQYLADLNVPIVGLGAEPVHENMVSWHHYTVPAGSSTVWGDFIR-RSAMVDVALNAVHDYHRQLVDSLQAAGVSVDINFEVTAETTSFEALARQMKAANIDTLTGVITPDVLTQILPAARAAGVNLKTVLLSLGYDRALLTDLGPALAGTNIYISFVPFELNTPAHQRLLAAMTRYSPQTQPPE-----QESAVFGWLSADLFLHGLQAAGAC----------------------THQSFLQGLHSVH---LPKPVDLAKNRGQLGNCYYFMRISGDG................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 347
6 -14.100PF13433.6; A4YPA8_BRASO/30-401; Periplasmic binding protein domain  ali follow..  8  1........................IKIGILHSLSETILKDLMLMQVAEQNARKKIEPVVVDPASNWPLFAEKARELLVKDKVAAVFGCWTSVSRKSVLPVFEELNGLLYYPLEYEGEESYNIFYGSSVPDNKAVPAVDYLEVKRFVLEGTDYVYPRTSNKIIRAYLKTADDDIMENYTPFGFSDWQTEVAAIKKFGGSAVISTVNGDANVPFYKELGNQGVKAKDIPVIAFSVGEEELAGLDTKPQVGHLAAWSYFQSNTPENKAFIAKWRDYA-----KNPKRVTNDPMESAYILFHMWVQAVQQAGTADV----------------------DAVRQAMIGQKFKSPSGFEVVMGSNHHMAKPVMIGEIQSNGQFTI............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 354
7 -10.900PF04348.13; LPOA_HAEIN/39-568; LppC putative lipoprotein  ali follow..  11  207............LLTLLNFQQTNVSQIGLLLPLSGDGQITTIQSGFNDAKGNSTIPVQVFDTSMNSVQDIIAQA---KQAGIKTLVGPLKQNLDVILADPAQIQGMDVLALNATPNSRAICYYGLSPEEAESAANKMWNDGVRNPLVAMQNDLGQRVGNAFNVRWQQLAGTDANIRYYNLPADVTYFVQENNSNTTA--LYAVASPTELAEMKGYLTNIVPN------IYASSRASASATNTNTDFIAQMNGVQFKDTNSPQYQKLAKSTGGEYQLMR-----------YAMGADAWLLINQFNE--------------------------------LRQVPGYRLSGLTGILSADTNCN.................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. 517
8 -6.790PF07885.16; Q8U058_PYRFU/403-481; Ion channel  ali follow..  16  25.........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................SPLDYVYFSIVTATTLGGDIHPTGV-GKAIASAEAIFGMFMWAVFLTVFARKYM........................................................................................................................................................................................................................................................................... 78
9 -5.980PF11847.8; V5X6I4_MYCNE/1-670; Alpha-(1  ali follow..  12  45...............................................................................................................................................................................................................................................................................................................................................................................................................................................QNQAYGYLFPHFFLAGDLLGVP----------------TQRLWWALLLTVGFWGLLRVAEALGIGTTAARVV--------AAGAFAL------SPRVLTTLGAISSETLPMMLAPWVLLPVIYVLRGDPRIRLLAARSA-ALMGAVNAVATLTGCLAAIIWWAAHKPNRQWWRFTGWWLGCTALAVTWWAVALVLLGRISPPFLDYIESSGVTTRWLSLTEMLR------GT---DSWTPFVAPTATAGSPLVTGSVAVLATTLVAAAGLAGLAMASMPSRGRLIL----------------ILFVGVTALAVGYGLGSPIAAGVQLFLDADGTPLRNVHKLEPL.................................................................................................................................. 343
10 -5.880PF00946.19; Q6YIR9_FDLV8/10-1113; Mononegavirales RNA dependent RNA polymerase  ali follow..  8  276......................EPLALSYIQLRDPILDQLLKEDTILSTGEVKDFIELISEIINMGSVSEISEIFSFFRDKVRDHMCKPKVLDYETLQKGHAVFCSMIINGFRERHGGSWPPCFLPDYASSELKAVMAN-SFIGFK--FDKFEEVNLDEDLTIFMKDKALSPIRAEWDTVYPQENMQYSPGRSSTSRRLVFLEDMEFNPQDIIDYVVSGSYLIDQDFNISYSLKEKEIKQAGRLFAKMTYKMRAAQVLAESLVAHGVGKYFQENGMVKDEHELLKSLTTLSLAGVPRSRPGEDPSATEESKFVKIAQKGKEILRNNQTRRSTQESRDQDGLANEKHETVASFITTDLQKWRYESVILFAQRLDEIYGLPGFFEWLHKRLEKSVLYVADPNCPPDFRTKMSLEDTPDTGIFIHNPMG--------IEGYSISMIHLAAVQTGVRVSAVIQGDNQ-------------AVTTRVPVRMNYNQKKTECYKSTIRYFELRKVMGGLGHNL---KLNETSNQFFIYSKRIYFD---------SILPQGLKTISRCVF-----------------WSETLVDETRAACSNISTSLAKAVENGISPLLCYLLNAWKTLQQLHISLAFSINPTITKDLYGPILSSQDWMIIAVIVPSQLGGFNYMSLSRLFVRNIGDPLVAALADVKRYEIGLLTTAALTKFTTQVPGDSTELDWASDPYLSKSPNPMLEGLFHENTDEEDHDLARFLIDREIILPRVANVILDQSVTGARSAIAGLLDTTKTLIKNTANKGGLSNRTVS........................................................................................................ 1087
FFAS is supported by the NIH grant R01-GM087218-01
1 4 6 8 3 9   jobs submitted since Jan 1, 2011
Comments and questions to: webmaster
Selected papers from Godzik Lab
Ying Zhang, Ines Thiele, Dana Weekes, Zhanwen Li, Lukasz Jaroszewski, Krzysztof Ginalski, Ashley Deacon, John Wooley, Scott Lesley, Ian Wilson, Bernhard Palsson, Andrei Osterman, Adam Godzik. Three-Dimensional Structural View of the Central Metabolic Network of Thermotoga maritima. Science. 2009 Sep 18;325(5947):1544-9.

Mayya Sedova, Mallika Iyer, Zhanwen Li, Lukasz Jaroszewski, Kai W Post, Thomas Hrabe, Eduard Porta-Pardo, Adam Godzik Cancer3D 2.0:: interactive analysis of 3D patterns of cancer mutations in cancer subsets. Nucleic Acids Research, gky1098 2018; Published on November 8 2018.

Bourne PE, Allerston CK, Krebs W, Li W, Shindyalov IN, Godzik A.,Friedberg I, Liu T, Wild D, Hwang S, Ghahramani Z, Chen L, Westbrook J. The status of structural genomics defined through the analysis of current targets and structures. Pac Symp Biocomput. 2004;:375-86.